Suchergebnisse - "Lopinavir"

PubPharm (17)

1

The effect of protease inhibitor-based dual antiretroviral regimens on CD4/CD8 ratio during the first year of therapy in ART-naïve patients with HIV-infection

enthalten in: HIV medicine | 2021

von Figueroa, M. | Camiro-Zuñiga, A. | Belaunzaran-Zamudio, P. | +12

2

Efficacy of protease inhibitor monotherapy vs. triple therapy : meta-analysis of data from 2303 patients in 13 randomized trials

enthalten in: HIV medicine | 2016

von Arribas, J. | Girard, P. | Paton, N. | +5

3

Lopinavir and atazanavir in pregnancy : comparable infant outcomes, virological efficacies and preterm delivery rates

enthalten in: HIV medicine | 2016

von Perry, M. | Taylor, G. | Sabin, C. | +18

4

Improved serum cholesterol in paediatric patients switched from suppressive lopinavir-based therapy to boosted darunavir or atazanavir : an 18-month retrospective study

enthalten in: HIV medicine | 2014

von Xiang, N. | James, M. | Walters, S. | +2

5

A comparison of the long-term durability of nevirapine, efavirenz and lopinavir in routine clinical practice in Europe : a EuroSIDA study

enthalten in: HIV medicine | 2011

von Reekie, J. | Reiss, P. | Ledergerber, B. | +108

6

The HIV protease inhibitor lopinavir/ritonavir (Kaletra) alters the growth, differentiation and proliferation of primary gingival epithelium

enthalten in: HIV medicine | 2011

von Israr, M. | Mitchell, D. | Alam, S. | +3

7

Lopinavir protein binding in HIV-1-infected pregnant women

enthalten in: HIV medicine | 2010

von Aweeka, F. | Stek, A. | Best, B. | +65

8

Long-term (96-week) follow-up of antiretroviral-naïve HIV-infected patients treated with first-line lopinavir/ritonavir monotherapy in the MONARK trial

enthalten in: HIV medicine | 2010

von Ghosn, J. | Flandre, P. | Cohen-Codar, I. | +108

9

Identification of new genotypic cut-off levels to predict the efficacy of lopinavir/ritonavir and darunavir/ritonavir in the TITAN trial

enthalten in: HIV medicine | 2009

von Hill, A. | Marcelin, A. | Calvez, V.

10

Antiviral activity and safety of aplaviroc, a CCR5 antagonist, in combination with lopinavir/ritonavir in HIV-infected, therapy-naïve patients : results of the EPIC study (CCR100136)

enthalten in: HIV medicine | 2009

von Yeni, P. | Lamarca, A. | Berger, D. | +85